Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (May 2021)
27 slides from Moleculin Biotech's investor presentation, May 19, 2021
Slide 1: Better Treatments, More Tomorrows
—~ Moleculin Better Treatments, More Tomorrows INVESTOR PRESENTATION / MAY 2021 MOLECULIN.COM / NASDAQ: MBRX
Slide 2: Disclaimer
DISCLAIMER AAll statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,
Slide 3: We are committed to solving the toughest challenges
We are committed to solving the toughest challenges in highly resistant cancers and viruses. Through our extensive network of world-renowned research organizations, we aim to develop better treatments that can make a real impact in people’s lives. = w~ Moleculin
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS CORE TECHNOLOGIES originated and licensed from MD Anderson Advancing Three Core Technologies DE-RISKED OPPORTUNITY with internally and externally funded development programs WP1066 Next genet Immune / Antimetabolites UP TO7 intended clinical studies with data readouts over the
Slide 5: Internally Funded Development Pipeline
INTERNALLY FUNDED DEVELOPMENT PIPELINE Multiple Value Driving Milestones PROGRAM INDICATION PRECLINICAL PHASE PHASE2 UPCOMING MILESTONES Acute Myeloid EE -.) Topline interim results from Phase 1/2 single agent study expected H2 2021 Aimaniyeli Leukemia Initiation of Phase 2 combo (Ara-C) ay study ta
Slide 6: Externally Funded Development Pipeline
EXTERNALLY FUNDED DEVELOPMENT PIPELINE Multiple Value Driving Milestones PROGRAM INDICATION PRECLINICAL PHASE PHASE? UPCOMING MILESTONES Initiation of EU Phase 1/2 study STS Lt Mets Annamycin ngnets targeted 2021 Initiation of Phase 2 study targeted ai SSSL_\_SSp Whee ch 2022 — Seeking Partner Topli
Slide 7: Preeminent Science Advisory Board
PREEMINENT Waldemar Priebe, PhD \ MD Anderson - ‘Gancer Center I Paul Waymack, MD, SCD FDA PANCREATIC James Abbruzzese, MD. Dana-Farber W duke University ‘School of Medicine HEMATOLOGY oy Elihu Estey, MD Gp raronuren zs) jours Horns, Marty Tallman, MD Memorial Sloan Kettering Cn Jorge Cortes, MD ‘tu
Slide 8: Extensive Network of Renowned Partners and Collaborators
EXTENSIVE NETWORK OF RENOWNED PARTNERS AND COLLABORATORS MDAnderson MAYO CLINIC nter WPD.‘x* \ / BIOVIN Pharmaceuticals CoE —__ fa UNIVERSITY — - —_—_— OF IOWA ImQuest _————__ WMoleculin BioSciences EMORY ~~ wi w UNIVERSITY yf Vee. a Gri cornet @ var UNIVERSITAT unicame —— REGA INSTITUTE KU LEUVEN ~
Slide 9: Our Strategy
OUR STRATEGY | Advance to clinical Translational development Prioritize accelerated ‘hie ieee from bench to clinical proof approval pathwa Infigetion pomnete PI pproval p: ys ha Leveraging collaborationsto Utilize external Leading with multiple conserve resources funding shots on goal = i ~ Moleculi
Slide 10: Annamycin
ANNAMYCIN “Next generation” non-cardiotoxic anthracycline Key Regulatory Highlights o——_—___—_____—_® Orphan Drug Fast Track Designation Status Target Indications: 60,001 2 2 160,000 cases worldwide 30,000 cases worldwide? ) ~19,940 new cases annually (U.S.) } 20% to 50% of sarcomas X F metastasize
Slide 11: Annamycin: Next Generation Anthracycline
ANNAMYCIN: NEXTGENERATION ANTHRACYCLINE Sine Novel non-cardiotoxic anthracycline [| Demonstrated ability to overcome multidrug resistance >30x better accumulation in lungs than doxorubicin Tissue Distribution of Annamycin And Doxorubicin in Rats Potent topoisomerase-ll poison with a wider therapeuti
Slide 12: Ongoing Phase 1/2 Study for Treatment of AML
ONGOING PHASE 1/2 STUDY FOR TREATMENT OF AML Dose escalation from 120 mg to a max of 420 mg (currently at 240 mg) Topline Phase 1 Primary Endpoint: Establish Results Expected safety and MTD/RP2D H2 2021 Number of Subjects: 75 Duration: 21 Days 12 ~ Moleculin
Slide 13: Annamycin - AML Clinical Benefit to Date
ANNAMYCIN — AML CLINICAL BENEFIT TO DATE’ Patients? treated in both US and EU trials 7 Patients with CR/PR (at subtherapeutic dose levels) 15 Relapsed patients! treated in both US and EU trials 14% Refractory patients’ with PR 40% Relapsed patients! with CR/PR 67% 240 mg cohort patients! with CR/PR
Slide 14: Annamycin Upcoming Clinical Studies
BB ANNAMYCIN UPCOMING CLINICAL STUDIES Soft Tissue Sarcoma Phase 2 combination therapy: targeted H2 2021 U.S. Phase 1/2: targeted 2021 Annamycin plus Ara-C Multi-center Intra-patient dose escalation New published mouse model data shows much EU Phase 1/2: targeted 2021 higher efficacy in AML when com
Slide 15: WP1066 and WP1220
WP1066 AND WP1220 First-in-class p-STAT3 inhibitors >13,000 new cases annually (U.S.)* Glioblastoma Multiforme >10,000 deaths annually (U.S.) (GBM) Key Regulatory Highlights 48% of all primary malignant Orphan Dr Rare Pediatric brain tumorst Designation Disease Designation Target Indications: 200-40
Slide 16: WP1066 and WP1220 Immune / Transcription Modulators
MM W/P1066 AND WP1220 IMMUNE / TRANSCRIPTION MODULATORS p-STAT3 inhibitor, a = key cancer and viral signaling pathway Also inhibits c-Myc and HIF-1a ~ 16 ~ Moleculin
Slide 17: Immune Modulation and Sensitizing to Radiation Therapy
IMMUNE MODULATION AND SENSITIZING TO RADIATION THERAPY + RADIATION Synergy with Radiation! B 100 = cas . > wrtee (9 mana) 3 = want oye) g + wet066 + waRT Targeting launch of Phase Study externally funded by: é 1/2 study in H2 2021 Ivey Foundation ol . 6 » © © Days ater GL2E cllnjoction E ees WP1066
Slide 18: WP1066 Treatment of Pediatric Brain Tumors, Including DIPG
mE WP1066 TREATMENT OF PEDIATRIC BRAIN TUMORS, INCLUDING DIFFUSE INTERSTITIAL PONTINE GLIOMA (DIPG) nee Escalating doses of 4, 6, 8, 12, Number of Subjects: 35 SRO e ea First Drug to Ever Show Activity in DIPG Study conducted at and Primary Endpoint: Establish funded by Emory University safety and M
Slide 19: WP1220 Treatment of Cutaneous T-Cell Lymphoma
me WP1220 TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL) Favorable Safety and Efficacy Demonstrated in Phase 1 Duration: 3 months of treatment Preparing to Launch Phase 2 Study in 2022 Response rate of 45% and a clinical benefit rate of 100% ODD and potential for | Seeking strategic partner | accalor
Slide 20: WP1122 Antimetabolites targeting glycolysis and glycosylation
WP1122 Antimetabolites targeting glycolysis and glycosylation with applications across cancer and viral indications >13,000 new cases annually (U.S.)? Glioblastoma Multiforme (GBM) Key Highlights >10,000 deaths annually (U.S.)? “48% of all primary malignant brain tumors* Prodrug of glucose Disruptio
Slide 21: Treatment of COVID-19
TREATMENT OF COVID-19 Multiple independent University studies show antiviral activity of 2-DG against SARS-CoV-2 2-DG was just given Emergency Use Authorization for treating COVID-19 in India based on Phase 2 results? WP1122 has substantially higher in vitro antiviral activity than 2-DG Pre-Assessme
Slide 22: ral AlvuoOdYod
ral AlvuoOdYod
Slide 23: Financial Snapshot
FINANCIAL SNAPSHOT NASDAQ: MBRX Strong Cash Position Funds Operations into 20231 Balance: Volume’ ~ ~ Moleculin
Slide 24: Management Team with Proven Executional Expertise
MANAGEMENT TEAM WITH PROVEN EXECUTIONAL EXPERTISE soliton ZENO PS pDrper ropes Deloitte. ~ ~ Moleculin
Slide 25: Target Value-Driving Milestones
25 TARGET VALUE-DRIVING MILESTONES 2021 2022 PROGRAM INDICATION | Phase 1/2 interim Data Phase 1/2 Topline Data ‘AML Comb with Ara-C Initiate Phase 2 Phase 2 Interim Data Phase 2 Topline Data ussts Phase 16/2 Interim Data Phase 1b/2 Interim Data GaM/Pancres File of IND Initiate Phase Initiate Phase
Slide 26: Investment Summary
INVESTMENT SUMMARY Extensive pipeline with multiple blockbuster market opportunities Lead program has potential to be first non- Pipeline provides cardiotoxic anthracycline \ Humerous value driving clinical and ae regulatory catalysts this year Fully-integrated team with proven track record of succe
Slide 27: Investor Relations
Investor Relations JTC Team 833.475.8247 mbrx@jtcicom —~ Moleculin Better Treatments, More Tomorrows Thank you! MOLECULIN.COM / NASDAQ: MBRX